

Colchicine Ameliorates High Glucose-Induced ICAM-1 and Fibronectin Expression in Renal Cells via Inhibiting Locally-Produced Angiotensin II

Eun Jin Kim, M.D.¹, Dong Ho Shin, M.D.¹, Jin Ji Li, Ph.D.²,
Sun Ha Lee, Ph.D.¹, Yong Kang Lee, M.D.¹, Hee-Jin Park, M.D.¹,
Hannah Seok, M.D.¹, Jung Tak Park, M.D.¹, Seung Hyeok Han, M.D.¹,
Tae-Hyun Yoo, M.D.¹ and Shin-Wook Kang, M.D.¹

Department of Internal Medicine¹, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 for Medical Science, Yonsei University, Seoul, Korea
Nephrology and Dialysis Unit, Department of Internal Medicine²,
The Affiliated Hospital, YanBian University Medical College, JILin, China

Purpose: A previous study has demonstrated that colchicine abrogated intercellular adhesion molecule (ICAM)-1 and fibronectin expression in renal cells exposed to high glucose media, but the underlying mechanism was not clarified. This study was undertaken to elucidate whether it was attributed to the inhibitory effect of colchicine on locally-produced angiotensin II (All) under diabetic conditions

Methods: Rat mesangial cells and NRK-52E cells were cultured in media containing 5.6 mM glucose (NG), NG+10⁻⁷ M All (NG+All), or 30 mM glucose (HG) with or without 10⁻⁸ M colchicine (Col) and/or 10⁻⁶ M L-158,809, an All type 1 receptor blocker (ARB). ICAM-1 and fibronectin mRNA and protein expressions were determined by real-time PCR (RT-PCR) and Western blot, respectively. All levels in conditioned media were determined by ELISA.

Results: All levels in conditioned media were significantly higher in HG-stimulated mesangial cells and NRK-52E cells compared to NG cells (p<0.05). ICAM-1 and fibronectin mRNA and protein expression were significantly increased in renal cells exposed to HG media (p<0.05 or p<0.01), and these increases were significantly ameliorated by colchicine or ARB treatment (p<0.05). Colchicine and ARB also significantly attenuated All-induced ICAM-1 and fibronectin expression (p<0.05). However, there was no additive inhibitory effect of colchicine and ARB on the increases in ICAM-1 and fibronectin expression.

Conclusion: Colchicine abrogated increased ICAM-1 and fibronectin expression in renal cells under diabetic conditions, which is partly mediated by inhibiting HG-induced locally-produced All. These findings provide a new renoprotective mechanism of colchicine in diabetic nephropathy in addition to its impact on leukocyte functions.

Key Words: Colchicine, Diabetic nephropathy, Renin-angiotensin system, ICAM-1, Fibronectin

INTRODUCTION

Diabetic nephropathy is generally considered a non-immune renal disorder; however, the infiltration of inflammatory cells within glomeruli and tubulointerstitium can be commonly observed in both human diabetic patients and animal models of diabetes¹⁻³. Monocytes/

Submitted: 29 August 2011, Revised: 14 September 2011

Accepted: 14 September 2011

Correspondence: Shin-Wook Kang, MD, PhD

Yonsei University College of Medicine, Department of Internal Medicine 134 Shinchon-Dong, Seodaemun-Gu Seoul, Korea, 120-752

Tel: 02)2228-1959, Fax: 02)393-6884

E-mail: kswkidney@yumc.yonsei.ac.kr

macrophages are the principle inflammatory cells found in the diabetic kidney and accumulating evidence has suggested that monocytes/macrophages play a critical role in the development and progression of glomerular and tubulointerstitial lesions in diabetic nephropathy. Even though strict blood glucose control and tight blood pressure control and the use of renin-angiotensin system (RAS) blockers have been the gold standard for the management of diabetic patients, the administration of anti-inflammatory agents has been recently shown to reduce inflammatory cell infiltration and to prevent renal injury in experimental diabetic animals⁴⁻⁶. Irradiation also had a beneficial effect on diabetic nephropathy via an anti-inflammatory mechanism⁷. These findings suggest that an inflammatory process may also contribute to the pathogenesis of diabetic nephropathy and that drugs possessing anti-inflammatory action can be used for preventing nephropathy in diabetic patients.

Colchicine is an 'old' drug commonly used to relieve pain in acute gout and is known to inhibit the function and motility of granulocytes and other motile cells⁸. In addition, colchicine was demonstrated to prevent experimental pulmonary and hepatic fibrosis⁹⁻¹². Moreover, recent studies showed that colchicine prevented renal injury in an animal model of chronic cyclosporine nephrotoxicity and in experimental diabetic rats via its anti-inflammatory action^{6, 13}. Furthermore, we previously found that colchicine abrogated intercellular adhesion molecule (ICAM)-1 and fibronectin expression in renal cells exposed to high glucose medium⁶. However, the underlying mechanism how colchicine ameliorates increased ICAM-1 and fibronectin expression under diabetic conditions was not clarified. Since a previous study suggested that colchicine may indirectly inhibit the action of AII^{14, 15}, we surmised that colchicine may inhibit locally-produced angiotensin II under diabetic conditions, resulting in reduced ICAM-1 and fibronectin expression. In this study, we investigated the effect of colchicine on the expression of ICAM-1 and fibronectin in high glu-

cose- and angiotensin II (AII)-stimulated mesangial cells and tubular epithelial cells. In addition, the effects of colchicine on high glucose-induced ICAM-1 and fibronectin expression were compared to those of L-158,809, an AII type 1 receptor (AT1R) blocker (ARB).

MATERIALS AND METHODS

1. Cell culture

Primary culture of rat mesangial cells were done as previously described¹⁶. Identification of mesangial cells was performed by their characteristic stellate appearance in culture and confirmed by immunofluorescent microscopy for the presence of actin, myosin, and Thy-1 antigen and the absence of factor VIII and cytokeratin (Synbiotics, San Diego, CA, USA). Mesangial cells and NRK-52E cells, immortalized rat tubular epithelial cells, were maintained in RPMI 1640 and DMEM medium, respectively, supplemented with 5% fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin, and 26 mM NaHCO₃, and were grown at 37°C in humidified 5% CO₂ in air. Subconfluent mesangial cells and NRK-52E cells were serum restricted for 24 hours, after which the medium was replaced by serum-free medium containing 5.6 mM glucose (NG), NG+24.4 mM mannitol (NG+M), NG+10⁻⁷ M AII (NG+AII), or 30 mM glucose (HG) with or without 10⁻⁸ M colchicine (Col) and/or 10⁻⁶ M L-158,809, an ARB. At 24 hours after the media change, cells were harvested and the conditioned culture media were collected.

2. Measurement of AII by ELISA

AII levels were determined in conditioned culture media using a commercial ELISA kit (Peninsula Laboratories, Belmont, CA, USA) by the avidin-streptavidin method, as previously described¹⁷. Briefly, samples or standards were incubated with anti-AII antibody and biotinylated AII (B-AII) in 96-well plates coated

with *Staphylococcus aureus* Protein A. After incubation, the unbound B-AII was removed by washing, and the bound B-AII was determined by reaction of streptavidin-HRP in the wells using TMB (3,3',5,5'-tetramethylbenzidine dihydrochloride) and H₂O₂ as a substrate. The reaction was terminated with 2 N HCl, and the color intensity in each well was read at 450 nm using an ELISA microtiter plate reader. The AII amount in each well was calculated from the standard curve and normalized with the total protein content, which had been previously determined by a modified Lowry method.

3. ¹²⁵I-AII binding

The AII binding assays were performed as described by Becker and Harris¹⁸. Briefly, after the incubation of cells with 30 mM glucose for 24 hours, confluent monolayers of cells were washed twice with ice-cold phosphate-buffered saline (PBS) containing 0.1% albumin (PBS-A), further incubated in PBS-A supplemented with ¹²⁵I-[Sar¹, Ile⁸] AII (10⁻¹⁰M) at 4°C for 4 hours, followed by three washes with the same ice-cold PBS-A. After solubilization in 0.5 N NaOH (1 mL), 900 µL of each sample were transferred into a scintillation tube and counted in a γ counter. Specific binding was determined by the equation (total binding - binding in the presence of 1 µM unlabeled AII). The radioactive counts in each sample normalized with the total protein content, which was previously determined by a modified Lowry method.

4. Total RNA extraction

Total RNA from renal cortical tissue was extracted as previously described¹⁶. Briefly, 100 µL of RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX, USA) was added to the renal cortical tissues lysed by the procedure of freezing and thawing repeated three times. Another 700 µL of RNA STAT-60 reagent was then added and the mixture was vortexed and stored

for 5 minutes at room temperature. Next, 160 µL of chloroform was added and the mixture was shaken vigorously for 30 seconds. After 3 minutes, the mixture was centrifuged at 12,000 × g for 15 minutes at 4°C and the upper aqueous phase containing the extracted RNA was transferred to a new tube. RNA was precipitated from the aqueous phase by adding 400 µL of isopropanol and then pelleted by centrifugation at 12,000 × g for 30 minutes at 4°C. The RNA precipitate was washed with 70% ice-cold ethanol, dried using a Speed Vac, and dissolved in DEPC-treated distilled water. RNA yield and quality were assessed based on spectrophotometric measurements at wavelengths of 260 and 280 nm. Total RNA from mesangial cells and NRK-52E cells was extracted in a similar way.

5. Reverse transcription

First strand cDNA was made by using a Boehringer Mannheim cDNA synthesis kit (Boehringer Mannheim GmbH, Mannheim, Germany). Two µg of total RNA extracted from renal cortex and cultured cells were reverse transcribed using 10 µM random hexanucleotide primer, 1 mM dNTP, 8 mM MgCl₂, 30 mM KCl, 50 mM Tris-HCl, pH 8.5, 0.2 mM dithiothreitol, 25 U RNase inhibitor, and 40 U AMV reverse transcriptase. The mixture was incubated at 30°C for 10 minutes and 42°C for 1 hour followed by inactivation of the enzyme at 99°C for 5 minutes.

6. Real-time polymerase chain reaction (Real-time PCR)

The primers used for MCP-1, ICAM-1, fibronectin, and 18s amplification were as follows: ICAM-1 sense 5'-AGGTA TCCATCCATCCCAC-3', antisense 5'-GCCGAGGTTCTCGTCTTC-3'; fibronectin sense 5'-TGACAACCTGCCGTAGACCTGG-3', antisense 5'-TAC TGGTTGTAGGTGTGGCCG-3'; and 18s sense 5'-AGTCCCTGCCCTTTGT ACACA-3', antisense 5'-GATCCGAGGGCCTCACTAAAC-3'. cDNAs from 25

ng RNA of renal cortical tissue or cultured cells per reaction tube were used for amplification.

Using the ABI PRISM[®] 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), PCR was performed with a total volume of 20 μ L in each well, containing 10 μ L of SYBR Green[®] PCR Master Mix (Applied Biosystems), 5 μ L of cDNA, and 5 pM sense and antisense primers. Primer concentrations were determined by preliminary experiments that analyzed the optimal concentrations of each primer. Each sample was run in triplicate in separate tubes to permit quantification of the gene normalized to the 18s rRNA. The PCR conditions were as follows: 35 cycles of denaturation at 94.5°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 1 minute. Initial heating at 95°C for 9 minutes and final extension at 72°C for 7 minutes were performed for all PCRs.

After real-time PCR, the temperature was increased from 60 to 95°C at a rate of 2°C/min to construct a melting curve. A control without cDNA was run in parallel with each assay. The cDNA content of each specimen was determined using a comparative CT method with $2^{-\Delta\Delta CT}$. The results are given as relative expression of ICAM-1 and fibronectin normalized to the expression of the 18s housekeeping gene.

7. Western blot analysis

Renal cortical tissue and cultured cells harvested from plates were lysed in sodium dodecyl sulfate (SDS) sample buffer (2% sodium dodecyl sulfate, 10 mM Tris-HCl, pH 6.8, 10% [vol/vol] glycerol), treated with Laemmli sample buffer, heated at 100°C for 5 minutes, and electrophoresed in an 8% acrylamide denaturing SDS-polyacrylamide gel. Proteins were then transferred to a Hybond-ECL membrane using a Hoeffer semidry blotting apparatus (Hoeffer Instruments, San Francisco, CA, USA), and the membrane was then incubated in blocking buffer A (1 \times PBS, 0.1% Tween-20, and 8% nonfat milk) for 1 hour at room temperature, followed by an overnight incubation

at 4°C in a 1:1,000 dilution of polyclonal antibodies to rat ICAM-1 (R&D systems, Minneapolis, MN, USA), fibronectin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), or β -actin (Sigma, St. Louis, MO, USA). The membrane was then washed once for 15 minutes and twice for 5 minutes in 1 \times PBS with 0.1% Tween-20. Next, the membrane was incubated in buffer A containing a 1:1,000 dilution of horseradish peroxidase-linked donkey anti-goat IgG (Amersham Life Science, Inc., Arlington Heights, IL, USA). The washes were repeated, and the membrane was developed with a chemiluminescent agent (ECL; Amersham Life Science, Inc.). The band densities were measured using TINA image software (Raytest, Straubenhardt, Germany).

8. Statistical analysis

All values are expressed as the mean \pm standard error of the mean (SEM). Statistical analysis was performed using the statistical package SPSS for Windows Ver. 11.0 (SPSS, Inc., Chicago, IL, USA). Results were analyzed using the Kruskal-Wallis non-parametric test for multiple comparisons. Significant differences by the Kruskal-Wallis test were further confirmed by the Mann-Whitney U test. p values less than 0.05 were considered to be statistically significant.

RESULTS

1. Effect of colchicine on AII concentrations

AII levels in conditioned media were significantly higher in HG-stimulated mesangial cells (7.21 \pm 1.12 pg/ μ L) and NRK-52E cells (3.11 \pm 0.53 pg/ μ L) compared to NG cells (4.38 \pm 0.64 pg/ μ L, 1.45 \pm 0.23 pg/ μ L, respectively) (N=5) (p<0.05). However, the increases in AII concentrations in HG cells were not significantly changed by colchicine (mesangial cells, 7.10 \pm 1.15 pg/ μ L; NRK-52E cells, 3.21 \pm 0.45 pg/ μ L) (N=5). On the other hand, mannitol had no effect on AII concentra-

tions in conditioned culture media.

2. Effect of colchicine on ¹²⁵I-AII binding

¹²⁵I-AII-specific binding was significantly reduced in HG-treated mesangial cells and NRK-52E cells compared to NG cells, but colchicine had no significant effect on ¹²⁵I-AII-specific binding in cells exposed to NG or HG medium (Fig. 1).

3. Effect of colchicine on high glucose- and AII-induced ICAM-1 expression

ICAM-1 mRNA expression assessed by real-time PCR was significantly induced in HG-stimulated mesangial cells (p<0.01) and NRK-52E cells (p<0.05). AII also significantly increased ICAM-1 mRNA ex-




Fig. 1. ¹²⁵I-AII-specific binding in mesangial cells (A) and NRK-52E cells (B) cultured in 5.6 mM glucose (NG), NG+10⁻⁸ M colchicine (NG+Col), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or HG+10⁻⁸ M colchicine (HG+Col) (N=5). ¹²⁵I-AII-specific binding was significantly decreased in HG-stimulated mesangial cells and tubular epithelial cells compared to NG cells. However, colchicine had no significant effect on ¹²⁵I-AII-specific binding in cells exposed to NG or HG medium. *p<0.05 vs. NG cells.

pression in cultured mesangial cells (p<0.01) and NRK-52E cells (p<0.01) compared to NG cells. The ICAM-1 mRNA/18s rRNA ratios were 2.1- and 2.0-folds higher in HG-stimulated mesangial cells and tubular epithelial cells, respectively, and 2.2- and 2.3-folds higher in AII-stimulated mesangial cells and tubular epithelial cells, respectively. These increases in ICAM-1 mRNA expression in HG- and AII-stimulated cells were significantly abrogated by the administration of colchicine or L-158,809 (Fig. 2). The protein expression of ICAM-1 showed a si-




Fig. 2. ICAM-1 mRNA/18s rRNA ratios in mesangial cells (A) and NRK-52E cells (B) cultured in 5.6 mM glucose (NG), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or NG+10⁻⁷ M AII (NG+AII) with or without 10⁻⁸ M colchicine (Col) and/or 10⁻⁶ M L-158,809 (ARB) (N=6). The ICAM-1 mRNA/18s rRNA ratios were 2.1- and 2.2-folds higher in HG- and AII-stimulated mesangial cells, respectively, and 2.0- and 2.3-folds higher in HG- and AII-treated tubular epithelial cells, respectively. These increases in ICAM-1 mRNA expression in HG- and AII-stimulated renal cells were significantly abrogated by the administration of Col or ARB. However, there was no additive inhibitory effect of Col and ARB on the increase in ICAM-1 mRNA expression in cells exposed to HG or AII. *p<0.01 vs. NG cells, †p<0.05 vs. HG- and AII-treated cells, ‡p<0.05 vs. NG cells.

milar pattern to its mRNA expression (Fig. 3). On the other hand, there was no additive or synergistic effect of colchicine and L-158,809 on HG- and AII-induced ICAM-1 expression.

4. Effect of colchicine on high glucose- and AII-induced fibronectin expression

The fibronectin mRNA/18s rRNA ratios were significantly increased in HG-stimulated mesangial cells ($p < 0.01$) and NRK-52E cells ($p < 0.05$) relative to NG cells by 115.5% and 82.4%, respectively. In addition, there were significant increases in fibronectin mRNA expression in AII-stimulated mesangial cells ($p < 0.01$) and tubular epithelial cells ($p < 0.01$). These increases in fibronectin mRNA expression in HG- and AII-stimulated cells were significantly ameliorated with colchicine or L-158,809 treatment (Fig. 4). The expression of fibronectin protein was also significantly

induced in HG- and AII-stimulated cells, and colchicine and L-158,809 significantly attenuated these increases in fibronectin protein expression (Fig. 5). On the other hand, there was no additive or synergistic effect of colchicine and L-158,809 on HG- and AII-induced fibronectin expression

DISCUSSION

We previously found that colchicine prevented renal injury in experimental diabetic nephropathy via inhibiting ICAM-1 and fibronectin expression⁶⁾, but the underlying mechanism how it abrogated increased ICAM-1 and fibronectin expression under diabetic conditions has not clarified yet. In this study, it is demonstrated for the first time that colchicine ameliorates AII-induced ICAM-1 and fibronectin expression in cultured renal cells without any significant influence on binding of AII to its receptor, suggesting that the




Fig. 3. A representative Western blot of ICAM-1 in mesangial cells (MC) (A) and NRK-52E cells (tubular epithelial cells, TEC) (B) cultured in 5.6 mM glucose (NG), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or NG+ 10^{-7} M AII (NG+AII) with or without 10^{-8} M colchicine (Col) and/or 10^{-6} M L-158,809 (ARB) (representative of four blots). ICAM-1 protein expression was significantly increased in HG- and AII-stimulated cells compared to NG cells, and these increases were significantly ameliorated by colchicine or ARB treatment. However, there was no additive inhibitory effect of Col and ARB on the increase in ICAM-1 protein expression in cells exposed to HG or AII. β -actin protein expression was comparable among the groups. * $p < 0.05$ vs. NG cells, † $p < 0.05$ vs. HG- and AII-treated cells, †† $p < 0.01$ vs. NG cells.




Fig. 4. Fibronectin mRNA/18s rRNA ratios in mesangial cells **(A)** and NRK-52E cells **(B)** cultured in 5.6 mM glucose (NG), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or NG+ 10^{-7} M AII (NG+AII) with or without 10^{-8} M colchicine (Col) and/or 10^{-6} M L-158,809 (ARB) (N=6). The fibronectin mRNA/18s rRNA ratios were significantly increased in HG-stimulated mesangial cells and tubular epithelial cells compared to NG cells by 115.5% and 82.4%, respectively. In addition, there were significant increases in fibronectin mRNA expression in AII-treated renal cells. These increases in fibronectin mRNA expression in HG- and AII-stimulated cells were significantly attenuated by the administration of Col or ARB. However, there was no additive inhibitory effect of Col and ARB on the increase in fibronectin mRNA expression in cells exposed to HG or AII. * $p < 0.01$ vs. NG cells, † $p < 0.05$ vs. HG- and AII-treated cells, ‡ $p < 0.05$ vs. NG cells.

beneficial effect of colchicine may be mediated by inhibiting increased locally-produced AII under diabetic conditions.

Even though the diabetic milieu per se, hemodynamic changes, and local growth factors such as AII are considered mediators in the pathogenesis of diabetic nephropathy¹⁹⁾, the underlying pathways mediating these processes are still under investigation. Among these, numerous previous clinical and experimental

studies on diabetic nephropathy have demonstrated that RAS blockades reduced proteinuria and the progression of renal lesions, which cannot be explained merely by their antihypertensive effect²⁰⁻²²⁾. These findings suggest that RAS inhibition may have direct effects on various renal cells. Indeed, mounting evidence has shown that the local RAS exists in various renal cells and is activated under diabetic conditions. All RAS components were revealed to be present in proximal tubular cells²³⁾, mesangial cells^{17, 24)}, and podocytes²⁵⁾, and the expression of angiotensinogen, the substrate for AII, was increased in these cells under diabetic conditions^{17, 23-25)}. In addition, high glucose activated the local RAS leading to an increase in AII levels²³⁻²⁵⁾, known to induce ICAM-1, MCP-1, and fibronectin expression in mesangial cells²⁶⁻²⁸⁾ and renal tubular cells²⁹⁻³¹⁾. Taken together, activated local RAS under diabetic conditions seems to play an important role in the pathogenesis of diabetic nephropathy via facilitating inflammation and extracellular matrix (ECM) synthesis. In the present study, we also confirmed that AII levels were significantly higher in high glucose-conditioned media compared to NG media and that ARB significantly inhibited increased ICAM-1 and fibronectin expression in cultured mesangial cells and tubular epithelial cells exposed to high glucose media, suggesting that high glucose-induced AII may contribute to the enhanced expression of ICAM-1 and fibronectin in renal cells under diabetic conditions.

Colchicine is an alkaloid drug that has been used for many decades in acute gouty arthritis. Colchicine binds to tubulin molecules and inhibits their polymerization into microtubules, resulting in disruption of the mitotic spindles⁸⁾. Due to this basic property, colchicine is mainly considered to be an anti-mitotic drug. However, accumulating evidence has shown its additional effects on leukocytes and fibroblasts³²⁻³⁶⁾. Colchicine is known to alter leukocyte functions, such as chemotaxis, adhesion, and cytokine production³⁵⁾. In addition, colchicine inhibits the release of fibronectin and collagen to the extracellular space, reduces collagen-




Fig. 5. A representative Western blot of fibronectin in mesangial cells (MC) (A) and NRK-52E cells (tubular epithelial cells, TEC) (B) cultured in 5.6 mM glucose (NG), NG+24.4 mM mannitol (NG+M), 30 mM glucose (HG), or NG+10⁻⁷ M AII (NG+AII) with or without 10⁻⁸ M colchicine (Col) and/or 10⁻⁶ M L-158,809 (ARB) (representative of four blots). Fibronectin protein expression was significantly increased in HG- and AII-stimulated cells compared to NG cells, and these increases were significantly abrogated by colchicine or ARB treatment. However, there was no additive inhibitory effect of Col and ARB on the increase in fibronectin protein expression in cells exposed to HG or AII. β-actin protein expression was comparable among the groups. *; p<0.05 vs. NG cells, †p<0.05 vs. HG- and AII-treated cells, ‡p<0.01 vs. NG cells.

processing enzyme, stimulates tissue collagenase activity, and inhibits the proliferation of fibroblasts³³⁻³⁵. Based on these anti-inflammatory and anti-fibrotic effects of colchicine, it has been used effectively to treat various diseases such as familial Mediterranean fever^{37, 38}, primary biliary cirrhosis^{39, 40}, and Behcet's syndrome⁴¹.

The beneficial effects of colchicine have also been demonstrated in several experimental kidney disease models, including severe crescentic glomerulonephritis, chronic cyclosporine nephrotoxicity, and diabetic nephropathy via anti-inflammatory, anti-fibrotic, and anti-apoptotic mechanisms^{6, 13, 42-44}. In addition, colchicine was revealed to inhibit the increases in ICAM-1 and fibronectin expression under diabetic conditions both *in vivo* and *in vitro*⁶. In that study, however, the underlying mechanism how colchicine abrogated the increases in ICAM-1 and fibronectin expression under diabetic conditions was not elucidated, leaving us with

another question: how does colchicine inhibit the up-regulation of these genes expression under diabetic conditions? Zhou et al¹⁵ demonstrated that AII-induced nuclear factor-κB in renal tubular cells was significantly attenuated by coadministration of losartan, a selective ARB, or colchicine, a selective cytoskeleton microtubule inhibitor known to block receptor-mediated endocytosis. Moreover, another recent study using the same cell line showed that intracellular accumulation of AII in response to extracellular AII, which was mediated by AT1R, was significantly ameliorated by not only losartan but also colchicine¹⁴. These findings suggest extracellular AII may play a functional role through internalization via AT1R-mediated endocytosis and that colchicine may indirectly inhibit the action of AII. Taken together, we proposed that the inhibitory effect of colchicine on the expression of these genes may be attributed to the suppressed action of locally-produced AII under high glucose conditions

in renal cells. This hypothesis is supported by our findings that AII concentrations are increased in high glucose-conditioned culture media and that colchicine attenuates high glucose- and AII-induced ICAM-1 and fibronectin expression. Furthermore, the results of this study showing that ^{125}I -AII-specific binding was not changed by colchicine, indicating no significant direct effect of colchicine on the binding of AII to AT1R, and that there was no additive inhibitory effect of colchicine and ARB on ICAM-1 and fibronectin expression infer that colchicine and ARB may partly act on a common pathway under diabetic conditions.

In summary, colchicine abrogates increased ICAM-1 and fibronectin expression in renal cells under diabetic conditions, partly mediated by inhibiting high glucose-induced locally-produced AII. These findings provide a new renoprotective mechanism of colchicine in diabetic nephropathy in addition to its impact on leukocyte functions.

REFERENCES

- 1) Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K: The role of macrophages in diabetic glomerulosclerosis. *Am J Kidney Dis* 21:480-485, 1993
- 2) Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K: Cellular events in the evolution of experimental diabetic nephropathy. *Kidney Int* 47:935-944, 1995
- 3) Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. *Kidney Int* 65:116-128, 2004
- 4) Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. *Kidney Int* 63:209-216, 2003
- 5) Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, Kang SW, Han DS, Han JY, Cha DR: Effect of retinoic acid in experimental diabetic nephropathy. *Immunol Cell Biol* 82:568-576, 2004
- 6) Li JJ, Lee SH, Kim DK, Jin R, Jung DS, Kwak SJ, Kim SH, Han SH, Lee JE, Moon SJ, Ryu DR, Yoo TH, Han DS, Kang SW: Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy. *Am J Physiol Renal Physiol* 297:F200-F209, 2009
- 7) Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. *Diabetes* 49:466-475, 2000
- 8) Hastie SB: Interactions of colchicine with tubulin. *Pharmacol Ther* 51:377-401, 1991
- 9) Rennard SI, Bitterman PB, Ozaki T, Rom WN, Crystal RG: Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach of the fibrotic disorders. *Am Rev Respir Dis* 137:181-185, 1988
- 10) Ledwozyw A: The effect of colchicine and vinblastine on bleomycin-induced lung fibrosis in rats. *Acta Physiol Hung* 82:383-389, 1994
- 11) Rodriguez L, Cerbon-Ambriz J, Munoz ML: Effects of colchicine and colchicine in a biochemical model of liver injury and fibrosis. *Arch Med Res* 29:109-116, 1998
- 12) Liu CY, Gu ZL, Zhou WX, Guo CY: Effect of Astragalus complanatus flavonoid on anti-liver fibrosis in rats. *World J Gastroenterol* 11:5782-5786, 2005
- 13) Li C, Yang CW, Ahn HJ, Kim WY, Park CW, Park JH, Cha JH, Kim J, Kim YS, Bang BK: Colchicine suppresses osteopontin expression and inflammatory cell infiltration in chronic cyclosporine nephrotoxicity. *Nephron* 92:422-430, 2002
- 14) Li XC, Carretero OA, Navar LG, Zhuo JL: AT1 receptor-mediated accumulation of extracellular angiotensin II in proximal tubule cells: role of cytoskeleton microtubules and tyrosine phosphatases. *Am J Physiol Renal Physiol* 291:F375-F383, 2006
- 15) Zhuo JL, Carretero OA, Li XC: Effects of AT1 receptor-mediated endocytosis of extracellular Ang II on activation of nuclear factor-kappa B in proximal tubule cells. *Ann N Y Acad Sci* 1091:336-345, 2006
- 16) Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R: 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. *Kidney Int* 59:1354-1362, 2001
- 17) Singh R, Singh AK, Alavi N, Leehey DJ: Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. *J Am Soc Nephrol* 14:873-880, 2003
- 18) Becker BN, Harris RC: A potential mechanism for proximal tubule angiotensin II-mediated sodium flux associated with receptor-mediated endocytosis and arachidonic acid release. *Kidney Int* 50(Suppl 57):S66-S72, 1996
- 19) Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. *Kidney Int* 58(Suppl 77):S93-S98, 2000
- 20) Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The

- effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 329:1456-1462, 1993
- 21) Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345:861-869, 2001
 - 22) Gross ML, El-Shakmak A, Szabó A, Koch A, Kuhlmann A, Münter K, Ritz E, Amann K: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. *Diabetologia* 46:856-868, 2003
 - 23) Wang TT, Wu XH, Zhang SL, Chan JS: Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. *Kidney Int* 53:312-319, 1998
 - 24) Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA: High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. *Am J Physiol Renal Physiol* 286:F1039-F1045, 2004
 - 25) Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim JS, Kim HJ, Han SH, Lee JE, Han DS, Kang SW: Activation of the renin-angiotensin system within podocytes in diabetes. *Kidney Int* 71:1019-1027, 2007
 - 26) Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. *Kidney Int* 45:177-184, 1994
 - 27) Menè P, Fais S, Cinotti GA, Pugliese F, Luttmann W, Thierauch KH: Regulation of U-937 monocyte adhesion to cultured human mesangial cells by cytokines and vasoactive agents. *Nephrol Dial Transplant* 10:481-489, 1995
 - 28) Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor- κ B activation and monocyte chemoattractant protein-1 synthesis. *J Immunol* 161:430-439, 1998
 - 29) Ricardo SD, Levinson ME, DeJoseph MR, Diamond JR: Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. *Kidney Int* 50:2002-2010, 1996
 - 30) Ruperez M, Ruiz-Ortega M, Esteban V, Lorenzo O, Mezzano S, Plaza JJ, Egido J: Angiotensin II increases connective tissue growth factor in the kidney. *Am J Pathol* 163:1937-1947, 2003
 - 31) Li XC, Zhuo JL: Intracellular ANG II directly induces in vitro transcription of TGF- β 1, MCP-1, and NHE-3 mRNAs in isolated rat renal cortical nuclei via activation of nuclear AT1a receptors. *Am J Physiol Cell Physiol* 294:C1034-C1045, 2008
 - 32) Phelps P: Polymorphonuclear leukocyte motility in vitro. IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. *Arthritis Rheum* 13:1-9, 1970
 - 33) Harris ED Jr., Krane SM: Effects of colchicine on collagenase in cultures of rheumatoid synovium. *Arthritis Rheum* 14:669-684, 1971
 - 34) Dehm P, Prockop DJ: Time lag in the secretion of collagen by matrix-free tendon cells and inhibition of the secretory process by colchicine and vinblastine. *Biochim Biophys Acta* 264:375-382, 1972
 - 35) Diegelmann RF, Peterkofsky B: Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. *Proc Natl Acad Sci U S A* 69:892-896, 1972
 - 36) Rinehart JJ, Boulware T: Microfilament and microtubule function in human monocytes. *J Lab Clin Med* 90:737-743, 1977
 - 37) Goldfinger SE: Colchicine for familial Mediterranean fever. *N Engl J Med* 287:1302, 1972
 - 38) Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, Gafni J: A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. *N Engl J Med* 291:932-934, 1974
 - 39) Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA: A prospective trial of colchicine for primary biliary cirrhosis. *N Engl J Med* 315:1448-1454, 1986
 - 40) Lee YM, Kaplan MM: Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. *Am J Gastroenterol* 98:205-208, 2003
 - 41) Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamurudan V, Uysal O, Senocak M, Yazici H: A double-blind trial of colchicine in Behcet's syndrome. *Arthritis Rheum* 44:2686-2692, 2001
 - 42) McClurkin C Jr., Phan SH, Hsu CH, Patel SR, Spicker JK, Kshirsagar AM, Yuan WY, Wiggins RC: Moderate protection of renal function and reduction of fibrosis by colchicine in a model of anti-GBM disease in the rabbit. *J Am Soc Nephrol* 1:257-265, 1990
 - 43) Li C, Yang CW, Ahn HJ, Kim WY, Park CW, Park JH, Lee MJ, Yang JH, Kim YS, Bang BK: Colchicine decreases apoptotic cell death in chronic cyclosporine nephrotoxicity. *J Lab Clin Med* 139:364-371, 2002
 - 44) Disel U, Paydas S, Dogan A, Gulfiliz G, Yavuz S: Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF- β overexpression, apoptosis, and oxidative damage: an experimental animal study. *Transplant Proc* 36:1372-1376, 2004